SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

SG Americas Securities LLC lessened its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 27.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,768 shares of the company’s stock after selling 4,149 shares during the period. SG Americas Securities LLC’s holdings in Stoke Therapeutics were worth $119,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after purchasing an additional 38,446 shares in the last quarter. Exome Asset Management LLC bought a new stake in Stoke Therapeutics in the third quarter valued at approximately $2,170,000. Barclays PLC boosted its holdings in shares of Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after buying an additional 47,239 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Stoke Therapeutics by 338.2% in the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after buying an additional 255,028 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on STOK shares. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Chardan Capital started coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Trading Up 0.5 %

Shares of STOK opened at $10.32 on Wednesday. Stoke Therapeutics, Inc. has a 12 month low of $4.09 and a 12 month high of $17.58. The firm has a fifty day simple moving average of $11.06 and a 200 day simple moving average of $12.56. The stock has a market capitalization of $546.65 million, a price-to-earnings ratio of -4.91 and a beta of 0.95.

Insider Buying and Selling

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.